AVANIR PHARMACEUTICALS, INC CL A (AVNR1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Keith A. Katkin
Employees:
491
20 ENTERPRISE, SUITE 200, ALISO VIEJO, CA 92656
949-389-6700

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States.

Data derived from most recent annual or quarterly report
Market Cap 3.223 Billion Shares Outstanding190.03 Million Avg 30-day Volume 5.986 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.31
Price to Revenue20.0784 Debt to Equity0.0 EBITDA-44.549 Million
Price to Book Value8.448 Operating Margin-40.289 Enterprise Value2.035 Billion
Current Ratio9.373 EPS Growth0.415 Quick Ratio9.183
1 Yr BETA 1.5293 52-week High/Low 0.0 / Profit Margin-43.8463
Operating Cash Flow Growth25.6305 Altman Z-Score39.6645 Free Cash Flow to Firm -41.029 Million
View SEC Filings from AVNR1 instead.

View recent insider trading info

Funds Holding AVNR1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVNR1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SIFFERT JOAO MD SVP, R&D

  • Officer
314,192 2014-12-18 0

OCAMPO CHRISTINE VICE PRESIDENT, FINANCE

  • Officer
108,797 2014-12-16 0

KATKIN KEITH PRESIDENT AND CEO

  • Officer
  • Director
914,249 2014-12-15 0

PALEKAR ROHAN SVP & CHIEF COMMERCIAL OFFICER

  • Officer
302,806 2014-11-28 0

CORRIGAN MARK

  • Director
0 2014-03-18 0

NEVINNY CORINNE H

  • Director
80,050 2014-02-12 0

WHEELER CRAIG A

  • Director
400,394 2014-02-12 0

PODLESAK DENNIS

  • Director
336,394 2014-02-12 0

MAZZO DAVID J

  • Director
336,394 2014-02-12 0

BISHOP HANS EDGAR

  • Director
93,350 2014-02-12 0

WHITCUP SCOTT M

  • Director
306,494 2013-02-14 0

MATHEWS CHARLES

  • Director
276,969 2012-03-06 0

AUSTIN STEPHEN G

  • Director
270,094 2012-02-16 0

KAYE RANDALL SR. VP, CHIEF MEDICAL OFFICER

  • Officer
78,190 2011-09-09 0

SIBOLD WILLIAM JOHN

  • SVP & CHIEF COMMERCIAL OFFICER
20,000 2011-05-03 0

CLARUS LIFESCIENCES I, L.P.

CLARUS VENTURES I GP, L.P.

CLARUS VENTURES I, LLC

LIPTAK ROBERT

SIMON NICHOLAS

HENNER DENNIS

GALAKATOS NICHOLAS

WHEELER KURT

STEINMETZ MICHAEL

  • 10% Owner
No longer subject to file 2010-12-03 0

MOORIN JAY

SCHREIBER ALAIN

  • 10% Owner
7,125,754 2009-10-09 0

VIVO VENTURES FUND VI, L.P.

VIVO VENTURES VI, LLC

  • 10% Owner
8,049,553 2009-08-11 0

THOMAS PAUL

  • Director
50,683 2007-03-01 0

SILVERSTEIN JONATHAN

  • Director
2,385,942 2007-03-01 0

BRANDT ERIC PRESIDENT, CEO & DIRECTOR

  • Officer
  • Director
231,225 2006-09-06 0

HOPEREESE THERESA VP, HUMAN RESOURCES

  • Officer
0 2006-08-16 0

ORBIMED ADVISORS LLC

ISALY SAMUEL D

ORBIMED CAPITAL II LLC

  • Director
1,706,137 2006-05-31 0

BERG JAMES E VICE PRESIDENT, CLINICAL

  • Officer
53,000 2006-05-30 0

EMANUELE ROBERT MARTIN V P, BUSINESS DEVELOPMENT

  • Officer
1,000 2006-05-25 0

PUNTORIERO MICHAEL J SENIOR VP, FINANCE, CFO

  • Officer
8,125 2006-05-25 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments